{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T02:44:11Z","timestamp":1782787451686,"version":"3.54.5"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":77,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Ophthal Inflamm Infect"],"DOI":"10.1186\/s12348-026-00575-0","type":"journal-article","created":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T09:49:03Z","timestamp":1776160143000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Relapse of retinal vasculitis after a non-medical biosimilar switch: a case report"],"prefix":"10.1186","volume":"16","author":[{"given":"Georges","family":"AbouKasm","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Albini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,14]]},"reference":[{"issue":"6","key":"575_CR1","doi-asserted-by":"publisher","first-page":"e1903","DOI":"10.1097\/mjt.0000000000000391","volume":"23","author":"L Isakov","year":"2016","unstructured":"Isakov L, Jin B, Jacobs IA (2016) Statistical Primer on Biosimilar Clinical Development. Am J Ther Nov\/Dec 23(6):e1903\u2013e1910. https:\/\/doi.org\/10.1097\/mjt.0000000000000391","journal-title":"Am J Ther Nov\/Dec"},{"issue":"5","key":"575_CR2","doi-asserted-by":"publisher","first-page":"e2315872","DOI":"10.1001\/jamanetworkopen.2023.15872","volume":"1","author":"BO Ascef","year":"2023","unstructured":"Ascef BO, Almeida MO, Medeiros-Ribeiro AC, Oliveira de Andrade DC, Oliveira Junior HA, de So\u00e1rez PC (2023) Therapeutic Equivalence of Biosimilar and Reference Biologic Drugs in Rheumatoid Arthritis: A Systematic Review and Meta-analysis. JAMA Netw Open May 1(5):e2315872. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.15872","journal-title":"JAMA Netw Open May"},{"key":"575_CR3","doi-asserted-by":"publisher","unstructured":"Yiu CH, Yau GTY, Wong ZH et al (2025) Comparative effectiveness and safety of biosimilars versus reference biologics in rheumatoid arthritis during treatment initiation: a systematic review of real-world evidence. Int J Clin Pharm Jun 25. https:\/\/doi.org\/10.1007\/s11096-025-01956-6","DOI":"10.1007\/s11096-025-01956-6"},{"key":"575_CR4","doi-asserted-by":"publisher","unstructured":"Nikitina V, Santi Laurini G, Montanaro N, Motola D (2023) Comparative safety profiles of oncology biosimilars vs. originators in Europe: an analysis of the EudraVigilance database. Cancers (Basel) Jul 19(14). https:\/\/doi.org\/10.3390\/cancers15143680","DOI":"10.3390\/cancers15143680"},{"key":"575_CR5","doi-asserted-by":"publisher","unstructured":"Kearsley-Fleet L, Rokad A, Tsoi MF et al (2023) Etanercept originator versus etanercept biosimilar for the treatment of rheumatoid arthritis as a first biologic: results from the BSRBR-RA. Rheumatology (Oxford). Dec 1. 62(12):3849\u20133857. https:\/\/doi.org\/10.1093\/rheumatology\/kead127","DOI":"10.1093\/rheumatology\/kead127"},{"issue":"8","key":"575_CR6","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1080\/14712598.2023.2176218","volume":"23","author":"A Sharma","year":"2023","unstructured":"Sharma A, Holz FG, Regillo CD et al (2023) Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER - survey). Expert Opin Biol Ther. Jul-Dec 23(8):851\u2013859. https:\/\/doi.org\/10.1080\/14712598.2023.2176218","journal-title":"Jul-Dec"},{"issue":"20","key":"575_CR7","doi-asserted-by":"publisher","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","volume":"19","author":"DF Martin","year":"2011","unstructured":"Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med May 19(20):1897\u20131908. https:\/\/doi.org\/10.1056\/NEJMoa1102673","journal-title":"N Engl J Med"},{"key":"575_CR8","doi-asserted-by":"publisher","unstructured":"Sharma A, Woo SJ, Kuppermann BD (2025) Aflibercept biosimilars \u2013 so near, yet so far. Expert Opinion on Biological Therapy. 05\/04 2025;25(5):459\u2013461. https:\/\/doi.org\/10.1080\/14712598.2025.2482663","DOI":"10.1080\/14712598.2025.2482663"},{"issue":"3","key":"575_CR9","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1007\/s40123-022-00488-w","volume":"11","author":"SM Hariprasad","year":"2022","unstructured":"Hariprasad SM, Gale RP, Weng CY, Ebbers HC, Rezk MF, Tadayoni R (2022) An Introduction to Biosimilars for the Treatment of Retinal Diseases: A Narrative Review. Ophthalmol Ther Jun 11(3):959\u2013982. https:\/\/doi.org\/10.1007\/s40123-022-00488-w","journal-title":"Ophthalmol Ther Jun"},{"key":"575_CR10","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.2147\/opth.S459085","volume":"18","author":"D Chakraborty","year":"2024","unstructured":"Chakraborty D, Boral S, Sinha TK et al (2024) Transitioning from Aflibercept to Biosimilar Ranibizumab in Neovascular AMD (The TRANSFORM Trial): A Multicenter Observational Study. Clin Ophthalmol 18:1819\u20131828. https:\/\/doi.org\/10.2147\/opth.S459085","journal-title":"Clin Ophthalmol"},{"key":"575_CR11","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1016\/j.ajo.2020.08.005","volume":"225","author":"JD Deaner","year":"2021","unstructured":"Deaner JD, Srivastava SK, Hajj-Ali RA et al (2021) Recurrence Rates of Inflammation after Switching from the Originator Infliximab to Biosimilar Infliximab-abda for Noninfectious Uveitis. Am J Ophthalmol May 225:172\u2013177. https:\/\/doi.org\/10.1016\/j.ajo.2020.08.005","journal-title":"Am J Ophthalmol May"},{"issue":"3","key":"575_CR12","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1177\/11206721231199778","volume":"34","author":"AH Dolinko","year":"2024","unstructured":"Dolinko AH, Morvey DE, Apoorva S, Chikovsky M, Anesi SD, Foster CS (2024) Effects of non-medical infliximab biosimilar switching in ocular inflammatory diseases: A case series from a tertiary care center. Eur J Ophthalmol May 34(3):774\u2013780. https:\/\/doi.org\/10.1177\/11206721231199778","journal-title":"Eur J Ophthalmol May"},{"issue":"4","key":"575_CR13","doi-asserted-by":"publisher","first-page":"288","DOI":"10.5152\/eurjrheum.2017.16112","volume":"4","author":"F Cantini","year":"2017","unstructured":"Cantini F, Niccoli L, Nannini C, Cassar\u00e0 E, Kaloudi O (2017) Rapid loss of efficacy of biosimilar infliximab in three patients with Beh\u00e7et\u2019s disease after switching from infliximab originator. Eur J Rheumatol Dec 4(4):288\u2013290. https:\/\/doi.org\/10.5152\/eurjrheum.2017.16112","journal-title":"Eur J Rheumatol Dec"},{"issue":"10086","key":"575_CR14","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1016\/s0140-6736(17)30068-5","volume":"10","author":"KK J\u00f8rgensen","year":"2017","unstructured":"J\u00f8rgensen KK, Olsen IC, Goll GL et al (2017) Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet Jun 10(10086):2304\u20132316. https:\/\/doi.org\/10.1016\/s0140-6736(17)30068-5","journal-title":"Lancet Jun"},{"issue":"1","key":"575_CR15","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1111\/apt.14997","volume":"49","author":"BG Feagan","year":"2019","unstructured":"Feagan BG, Lam G, Ma C, Lichtenstein GR (2019) Systematic review: efficacy and safety of switching patients between reference and biosimilar infliximab. Aliment Pharmacol Ther Jan 49(1):31\u201340. https:\/\/doi.org\/10.1111\/apt.14997","journal-title":"Aliment Pharmacol Ther Jan"},{"issue":"1","key":"575_CR16","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1111\/cts.13131","volume":"15","author":"S Mazza","year":"2022","unstructured":"Mazza S, Piazza OSN, Conforti FS et al (2022) Safety and clinical efficacy of the double switch from originator infliximab to biosimilars CT-P13 and SB2 in patients with inflammatory bowel diseases (SCESICS): A multicenter cohort study. Clin Transl Sci Jan 15(1):172\u2013181. https:\/\/doi.org\/10.1111\/cts.13131","journal-title":"Clin Transl Sci Jan"},{"issue":"1","key":"575_CR17","doi-asserted-by":"publisher","first-page":"16178","DOI":"10.1038\/s41598-020-73183-0","volume":"30","author":"MC Ditto","year":"2020","unstructured":"Ditto MC, Parisi S, Priora M et al (2020) Efficacy and safety of a single switch from etanercept originator to etanercept biosimilar in a cohort of inflammatory arthritis. Sci Rep Sep 30(1):16178. https:\/\/doi.org\/10.1038\/s41598-020-73183-0","journal-title":"Sci Rep Sep"},{"issue":"4","key":"575_CR18","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1007\/s40265-018-0881-y","volume":"78","author":"HP Cohen","year":"2018","unstructured":"Cohen HP, Blauvelt A, Rifkin RM, Danese S, Gokhale SB, Woollett G (2018) Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes. Drugs Mar 78(4):463\u2013478. https:\/\/doi.org\/10.1007\/s40265-018-0881-y","journal-title":"Drugs Mar"},{"issue":"3","key":"575_CR19","doi-asserted-by":"publisher","first-page":"613","DOI":"10.55563\/clinexprheumatol\/bf00j9","volume":"41","author":"R Scrivo","year":"2023","unstructured":"Scrivo R, Castellani C, Mancuso S et al (2023) Effectiveness of non-medical switch from adalimumab bio-originator to SB5 biosimilar and from ABP501 adalimumab biosimilar to SB5 biosimilar in patients with chronic inflammatory arthropathies: a monocentric observational study. Clin Exp Rheumatol Mar 41(3):613\u2013619. https:\/\/doi.org\/10.55563\/clinexprheumatol\/bf00j9","journal-title":"Clin Exp Rheumatol Mar"},{"key":"575_CR20","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.ajo.2020.10.013","volume":"225","author":"N Kumar","year":"2021","unstructured":"Kumar N, Follestad T, Sen HN, Austeng D (2021) A Systematic Switch From Originator Infliximab to Biosimilar Infliximab in Patients With Non-Infectious Uveitis. Am J Ophthalmol May 225:178\u2013184. https:\/\/doi.org\/10.1016\/j.ajo.2020.10.013","journal-title":"Am J Ophthalmol May"},{"issue":"8","key":"575_CR21","doi-asserted-by":"publisher","first-page":"1755","DOI":"10.1080\/09273948.2023.2295544","volume":"32","author":"SH Song","year":"2024","unstructured":"Song SH, Woo SJ (2024) Efficacy and Safety of Switching from Adalimumab Originator to SB5, Adalimumab Biosimilar for Noninfectious Uveitis. Ocul Immunol Inflamm Oct 32(8):1755\u20131759. https:\/\/doi.org\/10.1080\/09273948.2023.2295544","journal-title":"Ocul Immunol Inflamm Oct"},{"issue":"2","key":"575_CR22","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1177\/87551225241308475","volume":"41","author":"M Jankowska","year":"2025","unstructured":"Jankowska M, Dessureault K, MacDougall J, Sowers M, Merchand M, Kennedy AG (2025) Impact of Nonmedical Switches From Reference Infliximab to Biosimilars on Disease Control Within a Rheumatology Practice. J Pharm Technol Apr 41(2):83\u201389. https:\/\/doi.org\/10.1177\/87551225241308475","journal-title":"J Pharm Technol Apr"},{"issue":"1","key":"575_CR23","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1002\/art.40324","volume":"70","author":"L Tweehuysen","year":"2018","unstructured":"Tweehuysen L, van den Bemt BJF, van Ingen IL et al (2018) Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab. Arthritis Rheumatol Jan 70(1):60\u201368. https:\/\/doi.org\/10.1002\/art.40324","journal-title":"Arthritis Rheumatol Jan"},{"key":"575_CR24","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.3389\/fimmu.2020.01365","volume":"11","author":"N Kharlamova","year":"2020","unstructured":"Kharlamova N, Hermanrud C, Dunn N et al (2020) Drug Tolerant Anti-drug Antibody Assay for Infliximab Treatment in Clinical Practice Identifies Positive Cases Earlier. Front Immunol 11:1365. https:\/\/doi.org\/10.3389\/fimmu.2020.01365","journal-title":"Front Immunol"},{"key":"575_CR25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.aca.2019.08.044","volume":"16","author":"BL Duivelshof","year":"2019","unstructured":"Duivelshof BL, Jiskoot W, Beck A, Veuthey JL, Guillarme D, D\u2019Atri V (2019) Glycosylation of biosimilars: Recent advances in analytical characterization and clinical implications. Anal Chim Acta Dec 16:1089:1\u201318. https:\/\/doi.org\/10.1016\/j.aca.2019.08.044","journal-title":"Anal Chim Acta Dec"},{"key":"575_CR26","doi-asserted-by":"publisher","unstructured":"Hatamnejad A, Dadak R, Orr S, Wykoff C, Choudhry N (2023) Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment. BMJ Open Ophthalmol Jun 8(1). https:\/\/doi.org\/10.1136\/bmjophth-2022-001205.","DOI":"10.1136\/bmjophth-2022-001205"},{"issue":"7","key":"575_CR27","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1097\/iae.0000000000000902","volume":"36","author":"SS Wickremasinghe","year":"2016","unstructured":"Wickremasinghe SS, Janakan V, Sandhu SS, Amirul-Islam FM, Abedi F, Guymer RH, IMPLICATION OF RECURRENT OR, RETAINED FLUID ON OPTICAL COHERENCE TOMOGRAPHY FOR VISUAL ACUITY DURING ACTIVE TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION WITH A TREAT AND EXTEND PROTOCOL (2016) Retina Jul 36(7):1331\u20131339. https:\/\/doi.org\/10.1097\/iae.0000000000000902","journal-title":"Retina Jul"}],"container-title":["Journal of Ophthalmic Inflammation and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12348-026-00575-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-026-00575-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12348-026-00575-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T01:59:44Z","timestamp":1782784784000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12348-026-00575-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,14]]},"references-count":27,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["575"],"URL":"https:\/\/doi.org\/10.1186\/s12348-026-00575-0","relation":{},"ISSN":["1869-5760"],"issn-type":[{"value":"1869-5760","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,14]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. Ethical approval was not necessary and hence not obtained from the University of Miami institutional review board.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written informed consent for publication of clinical details and images was obtained from the participant.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"29"}}